Citizens Maintains Market Outperform on Nasus Pharma, Lowers Price Target to $18
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Jason N. Butler maintains Nasus Pharma (AMEX:NSRX) with a Market Outperform and lowers the price target from $19 to $18.
Citizens analyst Jason N. Butler maintains Nasus Pharma (AMEX:NSRX) with a Market Outperform and lowers the price target from $19 to $18.